CN110456060B - Application of EFCAB13 autoantibody detection reagent in preparation of lung cancer screening kit - Google Patents

Abstract

The invention relates to the field of in-vitro diagnostic reagents, in particular to an application of an EFCAB13 autoantibody detection reagent in preparing a lung cancer screening kit. The invention discovers for the first time that the level of autoantibodies of EFCAB13 protein in serum of a lung cancer patient is obviously higher than that of a healthy patient. According to the invention, the reagent for detecting the EFCAB13 protein autoantibody is used for preparing the lung cancer screening kit, so that effective screening of lung cancer can be realized.

Description

Application of EFCAB13 autoantibody detection reagent in preparation of lung cancer screening kit

Technical Field

The invention relates to the field of in-vitro diagnostic reagents, in particular to an application of an EFCAB13 autoantibody detection reagent in preparing a lung cancer screening kit.

Background

Lung cancer is one of the most common malignant tumors in the world, the morbidity and mortality of the lung cancer are on the rising trend year by year, the morbidity is at the top of the world at present, and the health and the life of human beings are seriously threatened.

The lung cancer is a disease good in occult, clinical symptoms are often shown only when the disease develops to the advanced stage, 70-80% of lung cancer patients are already at the middle and advanced stages when the lung cancer symptoms are diagnosed, cancer cells are diffused, the best curing time is missed, and the five-year survival rate is low. For early-stage lung cancer patients, the survival rate and the survival quality of the patients can be greatly improved by 5 years and more through timely treatment. Early diagnosis of lung cancer and effective screening are therefore of paramount importance.

The screening of the lung cancer refers to that the conventional physical examination is carried out on people without lung cancer related symptoms, and the lung cancer is found in time before the symptoms appear. If the lung cancer molecular marker in the plasma can be found, the molecular marker has important significance for prompting a clinician to take relevant treatment measures or decisions for a patient at an early stage.

Autoantibodies are antibodies produced by the body to self-organs, cells or cellular components. At present, autoantibodies to certain proteins have become markers for lung cancer, such as: p53, NY-ESO-1, CYFRA, etc. (Tang Z-M, Ling Z-G, Wang C-M, Wu Y-B, Kong J-L (2017) Serum tumor-associated autoimmune syndromes as diagnostic biological indicators for lung caner: analytical review and meta-analysis. PLoS ONE 12(7): e 0182117).

The SNP Id of EFCAB13 is rs118004742, located on chromosome 17q21.3, and found in relevant literature: although there is no evidence of association of EFCAB13 with prostate cancer, there are studies that show a significant difference in the expression level of EFCAB13 gene in prostate cancer patients from that of normal persons. So far, no report related to EFCAB13 protein autoantibody exists, and no prior art related to lung cancer exists.

Disclosure of Invention

The invention aims to provide a novel autoantibody lung cancer marker and application of a detection reagent of the marker in preparation of a lung cancer screening kit.

The technical scheme of the invention comprises the following steps:

application of a reagent for detecting an EFCAB13 protein autoantibody in preparation of a lung cancer screening kit.

As mentioned above, the reagent for detecting the EFCAB13 protein autoantibody is a reagent for enzyme-linked immunosorbent assay.

As for the above-mentioned use, the reagent for detecting the EFCAB13 protein autoantibody is a western blot reagent.

As mentioned above, the reagent for detecting the EFCAB13 protein autoantibody is a reagent for a protein chip detection method.

As used herein, the reagent for detecting EFCAB13 protein autoantibodies is a reagent for detecting EFCAB13 protein autoantibodies in human serum.

A lung cancer screening kit, which comprises a reagent for detecting an EFCAB13 protein autoantibody.

As the kit, the reagent for detecting the EFCAB13 protein autoantibody is a reagent for enzyme-linked immunosorbent assay or an enzyme-linked immunoassay reagent.

As the kit, the reagent for detecting the EFCAB13 protein autoantibody is a western blot reagent.

As the kit, the reagent for detecting the EFCAB13 protein autoantibody is a reagent for a protein chip detection method.

As the kit, the reagent for detecting the EFCAB13 protein autoantibody is a reagent for detecting the EFCAB13 protein autoantibody in human serum.

The invention provides a new lung cancer screening marker and a new lung cancer screening kit, which can realize effective screening of lung cancer; and the serum can be used as a detection sample, so that the harm to a patient is low. The invention has good application prospect.

Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.

The foregoing aspects of the present invention are explained in further detail below with reference to specific embodiments. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.

Hereinafter, "EFCAB 13 autoantibody" refers to "EFCAB 13 protein autoantibody".

Drawings

FIG. 1: lung cancer patients (LC), healthy control (NC) sera were compared for EFCAB13 autoantibody levels.

FIG. 2: lung cancer patients (LC) were analyzed by ROC with healthy controls (NC).

Detailed Description

Example 1 correlation of EFCAB13 autoantibodies in plasma with lung cancer

First, clinical data

59 lung cancer patients and 30 healthy controls were selected, and the basic information was as follows:

basic information	Patients with lung cancer	Healthy controls
			Number of people	59	30
Age(s)	54.5±7.6	42±8.9
			Proportion of male	37(62.7％)	13(46.7％)

Second, the detection principle

HuProt ^TM The human protein customizing chip is fixed with EFCAB13 protein, after incubation by adding serum, EFCAB13 autoantibodies (mainly including IgG and IgM antibodies and also some other types of antibodies) in the serum can be combined, the unbound antibodies and other proteins are removed by cleaning, anti-human IgM fluorescent labeled secondary antibody (cy5 label, showing red) and anti-human IgG fluorescent secondary antibody (cy3 label, showing green) are used for detection, signals are read by a fluorescence scanner, and the strength of the signals is positively correlated with the affinity and the quantity of the antibodies.

Third, the method

1) Rewarming: taking out the chip from a refrigerator at-80 deg.C, putting in a refrigerator at 4 deg.C for rewarming for half an hour, and then putting in room temperature for rewarming for 15 min;

2) and (3) sealing: fixing 14 blocks in the rewarming chip, adding sealing liquid into each block after fixing, placing on a side swing bed, and sealing at room temperature for 3 hr;

3) incubation of serum samples: after sealing is finished, pouring the sealing liquid completely, then quickly adding a serum incubation liquid prepared in advance, wherein each chip can incubate 14 serum samples, the sample loading volume of each serum sample is 200 mu L, and the shaking table is laterally swung at 20rpm and incubated overnight at 4 ℃ (the serum samples are frozen and thawed in a chromatography cabinet at 4 ℃, and the incubation liquid is added to dilute in a ratio of 1: 50 to obtain the serum incubation liquid);

4) cleaning: taking out the chip and the chip fence together, sucking out the sample, then quickly adding the PBST with the same volume, and repeating the steps for a plurality of times to ensure that no cross contamination exists among the serum samples when the chip fence is dismantled. After removing the chip fence, putting the chip into a chip cleaning box with cleaning solution, horizontally shaking at room temperature of 80rpm, and cleaning for 3 times, each time for 10 min;

5) and (3) secondary antibody incubation: transferring the chip into an incubation box added with 3mL of secondary antibody incubation liquid, laterally swinging a shaker at 40rpm, keeping out of the sun, and keeping at room temperature for 1 hr;

6) cleaning: the chip was removed (note that the upper surface of the chip was not touched or scratched), and placed in a chip washing cassette containing a washing solution, and washed 3 times 10min each time, on a horizontal shaker at room temperature and 80 rpm. After the completion, the mixture is washed for 2 times for 10min by ddH 2O;

7) drying;

8) scanning: scanning by using a crystal core LuxScan 10K microarray chip scanner;

9) data extraction: opening the corresponding GAL file (recording the position of protein in the chip), aligning the chip image and each array of the GAL file integrally, pressing an automatic alignment button, extracting data and storing.

Fourth, the results

The mean expression level of EFCAB13 autoantibodies in the plasma of lung cancer patients was 14.1SNR (fluorescence signal versus quantitative ratio), and the mean expression level of EFCAB13 autoantibodies in healthy control plasma was 23.5 SNR. The lung cancer group was statistically significant compared to healthy controls (p <0.05) (FIG. 1). The ROC analysis of the lung cancer group and healthy controls gave specificity of 96.6% and sensitivity of 20.3% (fig. 2), indicating that EFCAB13 autoantibodies can specifically distinguish lung cancer from healthy controls.

From the above results, it is clear that the difference in the level of EFCAB13 autoantibodies in the serum of lung cancer patients and non-lung cancer patients is significant, and the purpose of lung cancer screening can be achieved by detecting the level of EFCAB13 autoantibodies in the serum.

EXAMPLE 2 composition of the detection kit of the invention and method of use thereof

Kit composition

Detection kit (14 persons):

second, kit using method

Same as example 1, third part- "detection of EFCAB13 autoantibodies in serum".

The kit can screen the risk of the lung cancer of the people to be detected by detecting the level of the EFCAB13 autoantibody in serum: the risk of lung cancer is high if EFCAB13 autoantibody levels are low (relative to healthy humans) and low if EFCAB13 autoantibody levels are high. Can be used for the auxiliary diagnosis of clinical lung cancer, provides effective basis for patients to take relevant treatment measures or decisions, and has good clinical application prospect.

Claims (4)

1. The application of the reagent for detecting the EFCAB13 protein autoantibody in preparing a lung cancer screening kit is characterized in that the reagent for detecting the EFCAB13 protein autoantibody is a reagent for detecting the EFCAB13 protein autoantibody in human serum.

2. The use of claim 1, wherein said reagent for detecting autoantibodies to EFCAB13 protein is an enzyme-linked immunosorbent assay reagent.

3. The use according to claim 1 wherein the reagent for detecting autoantibodies to EFCAB13 protein is a western blot reagent.

4. The use of claim 1, wherein said reagent for detecting EFCAB13 protein autoantibodies is a reagent for a protein chip detection method.

Images